Monil Shah

Monil Shah has a solid background in the pharmaceutical and biotechnology industry, with over 18 years of work experience. Monil is currently serving as the Managing Director at IAA Consulting LLC since January 2019. Previously, they held the role of Chief Business Officer at Imugene Limited starting from June 2021.

Prior to that, Monil Shah worked as the Head of Development at Stingray Therapeutics in January 2018. Monil also served as the Chief Development Officer at WindMIL Therapeutics from October 2018 to June 2021. Moreover, they worked as a Scientific and Clinical Advisor at Brooklyn ImmunoTherapeutics from October 2018 to April 2021 and as the Chief Operating Officer from March 2017 to October 2018.

Monil Shah's experience extends to their time at Bristol-Myers Squibb, where they held the role of Global Medical Affairs Lead, Immuno-Oncology from March 2014 to March 2017. Monil also worked as the Vice President of Clinical Research and Development at Ventrus Biosciences from January 2011 to March 2014.

Furthermore, Monil Shah has held positions at Celgene, where they served as the Senior Director of Clinical Strategic Planning from April 2010 to January 2011 and as the Director of Oncology Clinical Research and Development from January 2008 to April 2010. Monil'scareer began at FibroGen as an Associate Director of Oncology Clinical Development from December 2005 to December 2007.

Monil Shah's early experience in the industry includes working as a Senior Clinical Research Manager in Medical Sciences at Amgen from December 2003 to December 2005. Throughout their career, they have showcased their expertise in various roles, contributing to the growth and success of the organizations they have been a part of.

Monil Shah obtained a Doctorate of Pharmacy from Rutgers University, where they studied from 1994 to 2000. Later, they pursued a Master in Business Administration in Healthcare Management from the Florida Institute of Technology, completing their studies between 2008 and 2012.